Fairvalue-Calculator Fairvalue-Calculator
EN DE

Raphas Co (214260) Fair Value & Analysis

Healthcare · KR · Market cap 61.9B KRW

Price8,020 KRW
Fair Value3,187 KRW
Upside-60.3%
Quality90/100
Evidence: Medium Range 2,462 KRW – 4,330 KRW

Fair value as of: Jun 25, 2026

Analysis

Raphas Co (214260) currently trades at 8,020 KRW, while our model-based Fair Value estimate is 3,187 KRW — implying the stock looks roughly 60.3% overvalued today. We read business quality at 90/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Raphas Co., Ltd. manufactures and sells biodegradable microneedles in Korea. The company offers skin care, medical device, whitening care, and wrinkle care under the Acropass brand; and health food product under the FitKong brand. It also supplies double-layer microneedle manufacturing technology; and provides original development manufacturing, and contract development and manufacturing organization services. The company was incorporated in 2006 and is based in Seoul, South Korea.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Raphas Co (214260) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 3,187 KRW versus a price of 8,020 KRW — about −60% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 214260?
Our 21-model fair value for Raphas Co is 3,187 KRW (as of Jun 25, 2026), built from audited fundamentals. The current price is 8,020 KRW.
What is the quality score of 214260?
Raphas Co has a Quality Score of 90/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.